Suchergebnisse - "Furman, Richard R"

PubPharm (237)

1

Cardiovascular events reported in patients with B-cell malignancies treated with zanubrutinib

enthalten in: Blood advances | 2024

von Moslehi, J. | Furman, R. | Tam, C. | +8

2

Tumor mutational load is prognostic for progression to therapy among high-count monoclonal B-cell lymphocytosis (HCMBL)

enthalten in: Blood advances | 2024

von Kleinstern, G. | Boddicker, N. | O'Brien, D. | +25

3

XPO1 Enables Adaptive Regulation of mRNA Export Required for Genotoxic Stress Tolerance in Cancer Cells

enthalten in: Cancer research | 2024

von Marullo, R. | Rutherford, S. | Revuelta, M. | +19

CommentIn: Cancer Res. 2024 Jan 2;84(1):3-5. - PMID 37902414

4

Hyperphosphorylation of BCL-2 family proteins underlies functional resistance to venetoclax in lymphoid malignancies

enthalten in: The Journal of clinical investigation | 2023

von Chong, S. | Zhu, F. | Dashevsky, O. | +21

5

Nine-year follow-up of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma

enthalten in: Blood advances | 2023

von Yamshon, S. | Chen, G. | Gribbin, C. | +9

6

Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial

enthalten in: Blood | 2023

von Seymour, J. | Byrd, J. | Ghia, P. | +15

CommentIn: Blood. 2023 Aug 24;142(8):679-680. - PMID 37616021

7

The immunomodulatory molecule TIGIT is expressed by chronic lymphocytic leukemia cells and contributes to anergy

enthalten in: Haematologica | 2023

von Arruga, F. | Rubin, M. | Papazoglou, D. | +13

8

Bioequivalence and Relative Bioavailability Studies to Assess a New Acalabrutinib Formulation That Enables Coadministration With Proton-Pump Inhibitors

enthalten in: Clinical pharmacology in drug development | 2022

von Sharma, S. | Pepin, X. | Burri, H. | +14

9

Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy : pooled analysis of 762 patients

enthalten in: Haematologica | 2022

von Brown, J. | Byrd, J. | Ghia, P. | +12

CommentIn: Haematologica. 2022 Jun 01;107(6):1489-1490. - PMID 34788988

10

Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton's tyrosine kinase inhibitor vecabrutinib in B-cell malignancies

enthalten in: Haematologica | 2022

von Allan, J. | Pinilla-Ibarz, J. | Gladstone, D. | +16

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[24]